Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter

Contact Us


Office Locations

USA Office

Two Bala Plaza, Suite 300
Bala Cynwyd, PA 19004
USA
T: +1 (484) 620-3236
F: +1 (610) 527-7631

e-mail: info (at) amyndas.com
              clinicaltrials (at) amyndas.com
investors (at) amyndas.com
@Amyndas

EU Office
27 Kyprou
Glyfada 16675
GREECE
T: +30 (694) 722-1847
e-mail: info (at) amyndas.com

 

Latest News

  • EUSTM (9th Congress): Novel Transformative Treatment for Periodontal Disease

  • Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

  • Review: Compstatins: the dawn of clinical C3-targeted complement inhibition

  • JCI Video: Complement C3 Inhibitor AMY-101 in Adults with Periodontal Inflammation – Clinical Trial

 

Latest Publications

  • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

  • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

  • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

  • Complement as a target in COVID-19?

 
 

Copyright © 2022 Amyndas Pharmaceuticals. All Rights Reserved.